Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia

[1]  J. Qian,et al.  H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia , 2018, Clinical Epigenetics.

[2]  J. Qian,et al.  Overexpression of miR‐216b: Prognostic and predictive value in acute myeloid leukemia , 2018, Journal of cellular physiology.

[3]  Min Yang,et al.  MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia , 2018, Journal of Translational Medicine.

[4]  K. Döhner,et al.  Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Falco,et al.  MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia , 2018, International journal of molecular sciences.

[6]  J. Qian,et al.  High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. , 2018, Gene.

[7]  Yunsuk Choi,et al.  Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome , 2017, The Korean journal of internal medicine.

[8]  Jianmin Yang,et al.  PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia , 2017, Journal of Translational Medicine.

[9]  Y. Ahn,et al.  Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis , 2017, BioMed research international.

[10]  J. Qian,et al.  Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies , 2017, Journal of cellular and molecular medicine.

[11]  W. Hahn,et al.  The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. , 2017, Blood.

[12]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[13]  Brock A. Humphries,et al.  The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy , 2015, Oncotarget.

[14]  J. Qian,et al.  Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome , 2014, PloS one.

[15]  J. Qian,et al.  Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. , 2014, International journal of clinical and experimental pathology.

[16]  Y. Xi,et al.  MiR-200, a new star miRNA in human cancer. , 2014, Cancer letters.

[17]  J. Qian,et al.  RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. , 2013, Clinical biochemistry.

[18]  M. Malumbres,et al.  Down-regulation of specific miRNAs enhances the expression of the gene Smoothened and contributes to T-cell lymphoblastic lymphoma development. , 2013, Carcinogenesis.

[19]  C. Bloomfield,et al.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Levine,et al.  How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? , 2012, Hematology. American Society of Hematology. Education Program.

[21]  J. Qian,et al.  U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2012, PloS one.

[22]  Qin Chen,et al.  IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome , 2012, Annals of Hematology.

[23]  Qin Chen,et al.  Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2011, PloS one.

[24]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[26]  J. Rowley.  Chromosomal translocations: revisited yet again. , 2008, Blood.

[27]  M. Korpal,et al.  The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.

[28]  J. Mendell,et al.  MicroRNAs in cell proliferation, cell death, and tumorigenesis , 2006, British Journal of Cancer.

[29]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[30]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[31]  Guoan Chen,et al.  Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. , 2018, Cancer biomarkers : section A of Disease markers.

[32]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.